- Home
- DQ vs XNCR Comparison
DQ vs XNCR Comparison
Compare DQ & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DQ
- XNCR
- Stock Information
- Founded
- DQ 2006
- XNCR 1997
- Country
- DQ China
- XNCR United States
- Employees
- DQ N/A
- XNCR N/A
- Industry
- DQ Semiconductors
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- DQ Technology
- XNCR Health Care
- Exchange
- DQ Nasdaq
- XNCR Nasdaq
- Market Cap
- DQ 1.4B
- XNCR 1.3B
- IPO Year
- DQ 2010
- XNCR 2013
- Fundamental
- Price
- DQ $21.77
- XNCR $15.74
- Analyst Decision
- DQ Hold
- XNCR Strong Buy
- Analyst Count
- DQ 5
- XNCR 8
- Target Price
- DQ $20.31
- XNCR $34.63
- AVG Volume (30 Days)
- DQ 798.4K
- XNCR 455.5K
- Earning Date
- DQ 02-27-2025
- XNCR 03-04-2025
- Dividend Yield
- DQ N/A
- XNCR N/A
- EPS Growth
- DQ N/A
- XNCR N/A
- EPS
- DQ N/A
- XNCR N/A
- Revenue
- DQ $1,310,019,000.00
- XNCR $85,164,000.00
- Revenue This Year
- DQ N/A
- XNCR N/A
- Revenue Next Year
- DQ $46.56
- XNCR $80.86
- P/E Ratio
- DQ N/A
- XNCR N/A
- Revenue Growth
- DQ N/A
- XNCR N/A
- 52 Week Low
- DQ $13.62
- XNCR $15.31
- 52 Week High
- DQ $30.85
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- DQ 58.99
- XNCR 21.76
- Support Level
- DQ $20.56
- XNCR $15.53
- Resistance Level
- DQ $22.24
- XNCR $16.69
- Average True Range (ATR)
- DQ 1.31
- XNCR 0.76
- MACD
- DQ 0.26
- XNCR 0.04
- Stochastic Oscillator
- DQ 70.90
- XNCR 9.57
About DQ DAQO New Energy Corp.
Daqo New Energy Corp is a polysilicon manufacturer based in China. The company manufactures and sells high-purity polysilicon to manufacturers who use it to make ingots, cells, and modules for solar power solutions. The polysilicon is packaged to meet crucible stacking, pulling, and solidification needs. All of the company's revenues come from the People's Republic of China.
About XNCR Xencor Inc.
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases such with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045, XmAb662 among others. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.